Corient Private Wealth LLC Buys 2,783,482 Shares of Merck & Co., Inc. $MRK

Key Points

• Corient Private Wealth LLC boosted its Merck stake by 114.7% in the fourth quarter, buying an additional 2.78 million shares and bringing its total holding to 5.21 million shares worth about $548.5 million.
• Merck received a notable catalyst when the U.S. FDA approved an expanded indication for CAPVAXIVE, allowing use in higher-risk children and adolescents ages 2 through 17, which could support future vaccine sales.
• The company recently beat quarterly earnings and revenue expectations, but the stock has still been trading lower recently as investors weigh growth prospects against broader portfolio concerns.

Corient Private Wealth LLC increased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 114.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,210,548 shares of the company's stock after purchasing an additional 2,783,482 shares during the period. Corient Private Wealth LLC owned approximately 0.21% of Merck & Co., Inc. worth $548,462,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $31,000. Finally, High Note Wealth LLC lifted its position in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of analyst reports. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. JPMorgan Chase & Co. increased their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research note on Monday, April 6th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price objective for the company. Finally, Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and a consensus target price of $128.18.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $114.04 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a fifty day simple moving average of $116.12 and a 200 day simple moving average of $113.60. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $125.14. The stock has a market capitalization of $281.65 billion, a PE ratio of 32.12, a P/E/G ratio of 2.60 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. During the same quarter last year, the company posted $2.22 earnings per share. The company's revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.